NCT00247650 is a Phase 2 clinical trial of Zoledronic Acid; Letrozole in Breast Cancer, sponsored by Novartis.

Who is sponsoring NCT00247650?

NCT00247650 is sponsored by Novartis.

What drugs are being tested in NCT00247650?

Interventions in NCT00247650: Zoledronic Acid; Letrozole.

What condition does NCT00247650 study?

NCT00247650 studies Breast Cancer.

Is NCT00247650 still recruiting?

NCT00247650 is currently completed. Last updated 28 February 2017.

Last reviewed 2017-02-28 · How we verify

NCT00247650

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Multi-Center Study Comparing Prolonged Primary Systemic Endocrine Therapy With Letrozole Alone or in Combination With Zoledronic Acid in Early Breast Cancer (NEOadjuvant Study in CANada)

Completed Phase 2 Last updated 28 February 2017

What this trial tests

Phase 2 trial testing Zoledronic Acid; Letrozole in Breast Cancer in 190 participants. Completed.

Timeline

1 September 2005

Primary endpoint
1 March 2007

Quick facts

Lead sponsor	Novartis
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	190
Start date	1 September 2005
Primary completion	1 March 2007
Sites	10 locations across Canada

Drugs / interventions tested

Zoledronic Acid; Letrozole — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Novartis — full company profile →

Who can join

65 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical response at 24 weeks

Sponsor's own description

This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Neville-Webbe HL, Coleman RE, Holen I. · · 2010 · cited 37× · PMID 20160726 · DOI 10.1038/sj.bjc.6605579
Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.
Adams A, Jakob T, Huth A, Monsef I, et al · · 2024 · cited 11× · PMID 38979716 · DOI 10.1002/14651858.cd013451.pub2

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Novartis trials

Trials by the same sponsor.

NCT06595069 — A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients · completed
NCT06632730 — Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain · completed
NCT06395909 — A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis · completed
NCT06516029 — Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Ascimini · completed
NCT06644638 — Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple S · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00247650 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis
Last refreshed: 28 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00247650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing